Associate Professor Will Herrington
Websites
- Medical Research Council Population Health Research Unit at the University of Oxford
-
Medical Research Council-UK
Professor David Kerr Clinician Scientist Award, 2018-2022
-
Kidney Research UK
Professor David Kerr Clinician Scientist Award, 2018-2022
- Health Data Research UK
-
British Heart Foundation
Centre of Research Excellence
- The EMPA-KIDNEY trial
- Mexico City Prospective Study
- The SHARP trial
- Cholesterol Treatment Trialists' Collaboration
- The UK-HARP3 trial
- The 3C trial
-
Oxford Kidney Unit
Honorary Consultant Nephrologist
-
Kidney Diseases: Improving Global Outcomes (KDIGO)
Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology
-
UK Renal Trials Network
Chair
Will Herrington
MA, MBBS, MD, FRCP
Associate Professor, Renal Studies Group
- Associate Professor, Renal Studies Group, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Univ. of Oxford
- Honorary Consultant Nephrologist, Oxford Kidney Unit
BIOGRAPHY
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3).
He is Chief Investigator of the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. The trial has now entered a post-trial observational follow-up phase and is developing health economic analyses. The biobank of leftover biological samples is being analysed to better understand the mechanism of action and metabolic effects of sodium glucose co-transporter-2 (SGLT-2) inhibitors like empagliflozin.
He is on a number of clinical practice guideline working groups, and co-chairs the UK Kidney Association guideline group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease. He is also interested in trial methodology and has chaired the UK Renal Trials Network since 2020.
His epidemiological research aims to better understand the key determinants of kidney disease development and progression (and its associated complications) using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. He is also focusing on how novel urine biomarkers could better assess effects of treatments on the kidney and predict progression.